SB
SLNO

Samsara BioCapital’s Soleno Therapeutics SLNO Stock Holding History

Samsara BioCapital’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-50,000
Closed -$1.67M – 39
2020
Q2 		$1.67M Buy
+50,000
New +$2.17M 0.54% 26

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital's SLNO Position: Q3 2020 in Review

Samsara BioCapital sold out of Soleno Therapeutics (SLNO) in Q3 2020, closing a stake of 50,000 shares — an estimated $1.67M sold.

Samsara BioCapital first reported a position in SLNO in Q2 2020 and held it in 1 quarter. The position peaked at $1.67M in Q2 2020. 66 funds tracked by Wall St. Rank hold SLNO as of Q3 2020.

  • Samsara BioCapital reported no remaining Soleno Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Samsara BioCapital sold 50,000 Soleno Therapeutics shares in Q3 2020, an estimated $1.67M.
  • Samsara BioCapital first reported a position in Soleno Therapeutics in Q2 2020 and held it in 1 quarter.
  • Samsara BioCapital's Soleno Therapeutics position peaked at $1.67M in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2020.

Based on Samsara BioCapital's 13F filing for Q3 2020, filed 16 Nov 2020.